Sionna Therapeutics, Inc. (SION) Stock

Sionna Therapeutics, Inc. (SION) is a Healthcare stock trading at $5.27 (as of 2026-08-21), with a market capitalization of $238.27M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sionna Therapeutics, Inc. is a biopharmaceutical company developing medicines aimed at normalizing the function of the cystic fibrosis transmembrane conductance regulator (CFTR). Its work is directed toward treatment approaches for patients with cystic fibrosis.

Understand Sionna Therapeutics, Inc.: how it makes money

Sionna Therapeutics is a biopharmaceutical company developing medicines for cystic fibrosis patients that normalize the CFTR (cystic fibrosis transmembrane conductance regulator) function.

The profit model is driven by clinical development execution, reflected in how many patients are dosed in Sionna’s cystic fibrosis trials (SION-719 and SION-451), because dosing is a core step toward generating any future product revenue.

Business quality (Weak): Early-stage operating visibility is limited to trial dosing metrics, and current financials show zero revenue and a very large operating loss.

Valuation: At 0× earnings, SION trades 100% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

  • Clinical execution signal from trial dosing: Sionna reports patient dosing activity in its cystic fibrosis programs, including Subjects Dosed in the SION-719 Trial and Subjects Dosed in the SION-451 Trial.
  • Clear therapeutic target and approach: The company’s stated goal is to develop medicines that normalize CFTR function for cystic fibrosis patients.

Bear case

  • No revenue reported: For the period ended 2026-03-31, revenue_b is 0.0B.
  • Very large operating loss: For the period ended 2026-03-31, operating_margin_pct is -1049.6, indicating substantial ongoing costs versus operating output.
  • Limited operating metrics provided: The provided operating KPIs focus on trial dosing (subjects dosed), with no included information on efficacy, safety, or trial outcomes.
Valuation — source: SEC EDGAR (first-party)
Price$5.27
Market Cap$238.27M
Price / Book0.90
Price / Sales20.39
FCF Yield-57.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$13.29M
Net Margin-566.1%
Revenue Growth (YoY)62.7%
EPS Growth (YoY)-88.2%
FCF Growth (YoY)26.2%
Financial Health — source: SEC EDGAR
Altman Z-Score6.33 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRA CAPITAL MANAGEMENT, L.P. ($397.09M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMichael Cloonan
Employees41
CountryUS
IPO Date2025-02-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Nature's Sunshine Products, Inc. (NATR)
  • Greenwich LifeSciences, Inc. (GLSI)
  • Akebia Therapeutics, Inc. (AKBA)
  • Whitehawk Therapeutics Inc (WHWK)
  • Organogenesis Holdings Inc. (ORGO)
  • Minerva Neurosciences, Inc. (NERV)
  • Avidity Biosciences, Inc. (RNA)
  • Immunic, Inc. (IMUX)
SION earnings history · SION institutional & insider holders · SION KPIs & operating metrics · SION financials · SION investor presentations & press releases · SION SEC filings · SION peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.